JP2012502927A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502927A5
JP2012502927A5 JP2011527166A JP2011527166A JP2012502927A5 JP 2012502927 A5 JP2012502927 A5 JP 2012502927A5 JP 2011527166 A JP2011527166 A JP 2011527166A JP 2011527166 A JP2011527166 A JP 2011527166A JP 2012502927 A5 JP2012502927 A5 JP 2012502927A5
Authority
JP
Japan
Prior art keywords
amino
acetic acid
methyl
indol
tetrahydropyrido
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011527166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502927A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2009/001321 external-priority patent/WO2010031183A1/en
Publication of JP2012502927A publication Critical patent/JP2012502927A/ja
Publication of JP2012502927A5 publication Critical patent/JP2012502927A5/ja
Pending legal-status Critical Current

Links

JP2011527166A 2008-09-22 2009-09-17 Crth2受容体拮抗薬としてのインドール誘導体 Pending JP2012502927A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19278708P 2008-09-22 2008-09-22
US61/192,787 2008-09-22
US17243909P 2009-04-24 2009-04-24
US61/172,439 2009-04-24
PCT/CA2009/001321 WO2010031183A1 (en) 2008-09-22 2009-09-17 Indole derivatives as crth2 receptor antagonists

Publications (2)

Publication Number Publication Date
JP2012502927A JP2012502927A (ja) 2012-02-02
JP2012502927A5 true JP2012502927A5 (OSRAM) 2012-10-25

Family

ID=42039054

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011527166A Pending JP2012502927A (ja) 2008-09-22 2009-09-17 Crth2受容体拮抗薬としてのインドール誘導体

Country Status (6)

Country Link
US (1) US8637671B2 (OSRAM)
EP (1) EP2346865B1 (OSRAM)
JP (1) JP2012502927A (OSRAM)
AU (1) AU2009295230A1 (OSRAM)
CA (1) CA2737483A1 (OSRAM)
WO (1) WO2010031183A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012502926A (ja) * 2008-09-22 2012-02-02 メルク カナダ インコーポレイテッド Crth2受容体アンタゴニストとしてのインドール誘導体
UA105039C2 (uk) 2009-02-24 2014-04-10 Мерк Шарп Енд Доме Корп. Похідні індолу як антагоністи рецептора crth2
MX2012010820A (es) 2010-03-22 2012-10-10 Actelion Pharmaceuticals Ltd Derivados de 3-(heteroaril-amino)-1, 2, 3, 4-tetrahidro-9h-carbazo l y sus uso como moduladores del receptor de prostaglandina d2.
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
CN103702985B (zh) 2010-12-23 2016-02-17 默沙东公司 作为crth2受体调节剂的喹喔啉和氮杂喹喔啉
WO2012087872A1 (en) 2010-12-23 2012-06-28 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as crth2 receptor modulators
WO2012140612A1 (en) * 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
AR086931A1 (es) 2011-06-17 2014-01-29 Merck Sharp & Dohme Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
UA117780C2 (uk) 2014-03-17 2018-09-25 Ідорсія Фармасьютікалз Лтд Похідні азаіндолоцтової кислоти та їх застосування як модуляторів рецепторів простагландину d2
RU2016140708A (ru) 2014-03-18 2018-04-18 Идорсиа Фармасьютиклз Лтд Производные азаиндол уксусной кислоты и их применение в качестве модуляторов рецептора простагландина d2
WO2016133793A1 (en) * 2015-02-16 2016-08-25 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
WO2016156588A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2017005766A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make tricycic alcohol intermediates of crth2 antagonists
WO2017005759A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make azaindole derivatives
UA123156C2 (uk) 2015-09-15 2021-02-24 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА ФОРМА (S)-2-(8-((5-ХЛОРПІРИМІДИН-2-ІЛ)(МЕТИЛ)АМІНО)-2-ФТОР-6,7,8,9-ТЕТРАГІДРО-5H-ПІРИДО[3,2-b]ІНДОЛ-5-ІЛ)ОЦТОВОЇ КИСЛОТИ, ЇЇ ЗАСТОСУВАННЯ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ
CA3161728A1 (en) 2019-12-20 2021-06-24 Mohamad Morsey Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
AU2022331122A1 (en) 2021-08-20 2024-02-15 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
BR0315681A (pt) * 2002-10-30 2005-09-06 Merck Frosst Canada Inc Composto e seus sais e hidratos farmaceuticamente aceitáveis, composição farmacêutica, métodos para o tratamento de doenças mediadas pela prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, composto ou um seu sal ou solvato farmaceuticamente aceitável, sal ou hidrato do composto, e, uso de um composto ou de um seu sal ou solvato farmaceuticamente aceitável
WO2006125179A1 (en) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
AU2006281937B2 (en) 2005-08-12 2011-11-17 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
TW200902016A (en) * 2007-05-22 2009-01-16 Taigen Biotechnology Co Ltd Kinesin inhibitors
KR20130069840A (ko) 2007-10-10 2013-06-26 케미텍 엘엘씨 Crth2 수용체 길항제로서의 헤테로고리 화합물
EP2344497B1 (en) * 2008-09-22 2014-03-05 Merck Canada Inc. Azaindole derivatives as crth2 receptor antagonists
JP2012502926A (ja) * 2008-09-22 2012-02-02 メルク カナダ インコーポレイテッド Crth2受容体アンタゴニストとしてのインドール誘導体
UA105039C2 (uk) * 2009-02-24 2014-04-10 Мерк Шарп Енд Доме Корп. Похідні індолу як антагоністи рецептора crth2

Similar Documents

Publication Publication Date Title
JP2012502927A5 (OSRAM)
JP5387997B2 (ja) 血管の収縮または拡張による疾患治療剤
JP2010509356A5 (OSRAM)
JP2010500293A5 (OSRAM)
RU2005107314A (ru) Пиримидопроизводные, характеризующиеся антипролиферативной активностью
JP2010536757A5 (OSRAM)
JP2008513499A5 (OSRAM)
TW201333012A (zh) 咪唑并吡咯啶酮化合物
JP6076498B2 (ja) ナンセンス突然変異抑制剤としてのピリミド[4,5−b]キノリン−4,5(3h,10h)−ジオン
JP2018502900A5 (OSRAM)
JP2012521428A5 (OSRAM)
JP2010500376A5 (OSRAM)
JP2009513703A5 (OSRAM)
JP2018168191A5 (OSRAM)
PT2592081T (pt) Derivado de tetrahidrocarbolina
JP2003528096A5 (OSRAM)
JP2003503449A5 (OSRAM)
JP2010522710A5 (OSRAM)
JP2010529969A5 (OSRAM)
JP2010527985A5 (OSRAM)
JP2010527984A5 (OSRAM)
JP2013507426A5 (OSRAM)
KR100718906B1 (ko) 디히드로나프탈렌 유도체 화합물 및 이 화합물을 유효성분으로 하는 약제
CN101133037B (zh) 六元杂环化合物及其用途
JP2005508969A5 (OSRAM)